By NeuralinkLearning Objectives
- Understand how Neuralink's N1 brain-computer interface works and what it enables for patients
- Identify the current status of clinical trials, patient outcomes, and regulatory milestones
- Evaluate the potential and limitations of brain-computer interfaces for medical and consumer applications
What Is Neuralink N1?
Neuralink N1 is a brain-computer interface (BCI) — a small device surgically implanted in the brain that reads neural signals and translates them into digital commands. As of early 2026, approximately 20 patients across the United States, United Kingdom, and Canada have received the N1 implant, all as part of clinical trials for people with paralysis or severe motor impairments.
The N1 device contains 1,024 electrode threads — ultra-thin, flexible wires thinner than a human hair — that are inserted into the motor cortex using the R1 surgical robot. These threads detect electrical signals from individual neurons as the patient thinks about moving. Neuralink's software decodes these neural signals in real time, translating thought into cursor movement, clicks, and other digital actions.
The first patient, Noland Arbaugh, achieved 9+ bits per second of cursor control — more than double the previous record for any brain-computer interface. Patients can browse the internet, play video games, use social media, send messages, and control computers entirely through thought. The upgraded N1 architecture features 128 thinner threads with less tissue displacement, reducing the risk of long-term tissue damage.
Neuralink is also developing Blindsight, a separate device targeting the visual cortex that aims to restore rudimentary vision for blind individuals. Blindsight received FDA Breakthrough Device Designation in September 2024, accelerating its regulatory pathway.
⚠️Warning
Clinical trial status: Neuralink N1 is not commercially available. All implants are part of FDA-regulated clinical trials for participants with qualifying medical conditions (quadriplegia, ALS, etc.)
Pricing
- Neuralink covers all costs including surgery
- Device
- And follow-up care
- Expected to be covered by insurance for qualifying medical conditions when approved
- No timeline for non-medical consumer applications
As a clinical-stage medical device, the N1 has no commercial price. Neuralink has indicated that eventual pricing will target insurance coverage for patients with qualifying conditions, similar to cochlear implants and deep brain stimulators.
Core Capabilities
Neural Signal Decoding
The N1's 1,024 electrodes read signals from individual neurons in the motor cortex — the brain region responsible for planning and executing movement. When a patient thinks about moving their hand, specific neurons fire in patterns that the N1 detects, amplifies, and transmits wirelessly to an external device. Neuralink's decoding algorithms translate these patterns into precise cursor movements, clicks, and gestures in real time. The system improves over time as the algorithms learn each patient's unique neural patterns.
Wireless Brain-Computer Control
The N1 is fully wireless — it charges through the skin via inductive charging (similar to a wireless phone charger) and transmits data via Bluetooth to a nearby computer or phone. Patients do not have any wires or external connectors. This wireless design enables natural, all-day use for browsing the internet, playing games, typing messages, and controlling smart home devices through thought alone. The device processes signals on-chip before transmitting, reducing latency and power consumption.
R1 Surgical Robot
The R1 surgical robot performs the implantation procedure with precision beyond human surgical capability. It inserts 1,024 ultra-thin electrode threads into the brain's surface while avoiding blood vessels detected via real-time imaging. The robotic approach reduces surgery time, minimizes tissue damage, and enables consistent placement across patients. The automated nature of the procedure is critical for scaling implantation beyond a few specialized neurosurgery centers.
Strengths
- Record-breaking performance: 9+ bits/sec cursor control — over double the previous BCI record, enabling practical daily use
- 1,024 channels: Far more electrodes than competing BCIs (most research systems use 100 or fewer channels), providing richer signal capture
- Fully wireless: No external wires or connectors — enables natural all-day use without visible hardware
- Robotic surgery: The R1 robot enables precise, repeatable implantation that can scale beyond elite neurosurgery centers
- Real patient outcomes: Patients are browsing the internet, playing games, and communicating — demonstrating practical (not just experimental) utility
- Blindsight potential: The visual cortex device could address blindness — a separate, equally transformative application
Limitations & Considerations
- Clinical trials only: Not commercially available — restricted to patients with qualifying conditions at approved trial sites
- Invasive surgery required: Brain surgery carries inherent risks including infection, bleeding, and tissue damage, even with robotic precision
- Long-term durability unknown: The implant has been in patients for under 2 years — 10+ year durability data does not yet exist
- Thread retraction observed: Early patients experienced some electrode threads pulling away from brain tissue, reducing signal quality (addressed in the upgraded architecture)
- Limited patient pool: ~20 patients is a very small sample — broader safety and efficacy data will take years of additional trials
- Ethical considerations: Brain-computer interfaces raise significant questions about privacy, cognitive autonomy, data security, and equitable access
Best Use Cases
| Scenario | Why Neuralink N1 |
|---|---|
| Quadriplegia / paralysis | Restores digital communication and computer control for people who cannot use their hands |
| ALS communication | Enables patients losing motor function to continue communicating via thought-controlled typing |
| Locked-in syndrome | Provides a communication channel for patients who are cognitively intact but cannot move or speak |
| Spinal cord injury research | Neural signal data advances understanding of motor cortex function and neural rehabilitation |
| Blindness (Blindsight) | Visual cortex stimulation aims to restore rudimentary vision for blind individuals |
When to choose alternatives:
- Non-invasive brain monitoring --> EEG-based BCIs (no surgery required, lower resolution but zero surgical risk)
- Eye-tracking computer control --> Tobii Dynavox (mature, commercially available assistive technology)
- Speech-based assistive tech --> Voice recognition systems for patients who retain speech ability
- Research-grade neural recording --> Blackrock Neurotech Utah Array (FDA-cleared, decades of research data)
Current Trial Status
- PRIME Study (US): FDA-approved clinical trial for patients with cervical spinal cord injury or ALS — primary trial site
- UK expansion: Approved by the UK's MHRA — implantations underway at partner hospitals
- Canada expansion: Health Canada approval for clinical trial participation
- The upgraded N1 architecture (128 thinner threads) is being used in newer implantations to address thread retraction
- Blindsight: Separate regulatory track — FDA Breakthrough Device Designation granted September 2024; human trials anticipated
- Monitor trial eligibility at neuralink.com/patient-registry if you or someone you know has a qualifying condition
📝Note
Historical context: Brain-computer interfaces have existed in research labs for decades, but Neuralink's combination of high channel count (1,024 electrodes), wireless operation, robotic surgery, and demonstrated practical utility (internet browsing, gaming) represents a step change in BCI capability and usability.
Key Takeaways
- Neuralink N1 is a brain-computer interface with 1,024 electrode threads, implanted in ~20 patients who can now control computers through thought
- The first patient achieved 9+ bits/sec cursor control — more than double the previous BCI record — enabling practical daily computer use
- The device is in clinical trials only (not commercially available), with surgery performed by the R1 robotic system
- Blindsight, a visual cortex implant for blindness, has FDA Breakthrough Device Designation and represents Neuralink's second major application
